{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"9"}],"units":"Participants"}],"description":"Occurrence, nature, and severity of adverse events","groups":[{"description":"Selinexor 60 mg PO days 1, 8, 15 Pomalidomide 4 mg PO on days 1-21 Dexamethasone 40 mg PO or IV on days 1, 8, 15, 22 28 day treatment cycles","id":"OG000","title":"Arm 1"},{"description":"Selinexor 80 mg PO days 1, 8, 15 Carfilzomib IV infusion 20 mg/m2 cycle 1, day 1, 56 mg/m2 cycle 1 day 8, 15. Cycle 2+ days 1, 8, 15.\n\nDexamethasone 40 mg IV or PO days 1, 8, 15, 22 28 day treatment cycle","id":"OG001","title":"Arm 3"},{"description":"Selinexor 80 mg PO days 1, 8, 15 Daratumumab 1,800mg/30,000 units subcutaneous injection on days 1, 8, 15, 22 of cycles 1 and 2, days 1, 15 of cycles 3-6, day 1 of cycles \\>6 Dexamethasone 40 mg PO or IV days 1, 8, 15, 22 28 day treatment cycle","id":"OG002","title":"Arm 2"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Outcome measure data table indicates number of patients who experienced adverse events on each arm. Refer to adverse events table for detailed information.","reportingStatus":"POSTED","timeFrame":"From first dose of study drug through 30 days after last dose of protocol required therapies","title":"Safety and Tolerability of Selinexor in Combination With Partner Backbone Agents","type":"SECONDARY","unitOfMeasure":"Participants"}